In February 1979 Hyland learnt of Behringwerke beginning clinical trials in 1978 in Germany on "Factor VIII Behringwerke" via a report to their head office, later confirmed by another Hyland employee. Read more about In February 1979 Hyland learnt of Behringwerke beginning clinical trials in 1978 in Germany on "Factor VIII Behringwerke" via a report to their head office, later confirmed by another Hyland employee.
Hyland had a research project aimed at eliminating NANBH in factor concentrates that was being hindered by a lack of manpower and adequate funding. Read more about Hyland had a research project aimed at eliminating NANBH in factor concentrates that was being hindered by a lack of manpower and adequate funding.
The concern that heated Factor 9 concentrates might cause thrombosis was one that had to be resolved before its product could be issued. As a result experiments in dogs were conducted prior to clinical trial in humans. Read more about The concern that heated Factor 9 concentrates might cause thrombosis was one that had to be resolved before its product could be issued. As a result experiments in dogs were conducted prior to clinical trial in humans.
BPL's work on heat treatment - regarding Factor 9 - only really started in 1982. Read more about BPL's work on heat treatment - regarding Factor 9 - only really started in 1982.
A surveillance of previously untreated patients for possible virus transmission by BPL Factor 8 and Factor 9 Concentrates, 8Y and 9A, was carried out in September 1986. Read more about A surveillance of previously untreated patients for possible virus transmission by BPL Factor 8 and Factor 9 Concentrates, 8Y and 9A, was carried out in September 1986.
In Parliament, Baroness Jean Trumpington made clear that NHS products derived from screened plasma would become available for distribution during August 1986 throughout the UK. Read more about In Parliament, Baroness Jean Trumpington made clear that NHS products derived from screened plasma would become available for distribution during August 1986 throughout the UK.
BPL and PFC recalled unheated Factor 9 in October 1985. Read more about BPL and PFC recalled unheated Factor 9 in October 1985.
BPL were in a position to issue information sheets which stated that the clinical trials of 8Y at six haemophilia centres showed that several patients had by then safely passed the point at which the first evidence of non-A non-B Hepatitis viral transmission would normally occur with non-heated Factor 8. Read more about BPL were in a position to issue information sheets which stated that the clinical trials of 8Y at six haemophilia centres showed that several patients had by then safely passed the point at which the first evidence of non-A non-B Hepatitis viral transmission would normally occur with non-heated Factor 8.
Dr Snape wrote to Dr Lane: "a significant number of HTLV-III Christmas disease patients, treated only with NHS IX and with no other risk factors, argues strongly for haste with manufacture of heated factor IX." Read more about Dr Snape wrote to Dr Lane: "a significant number of HTLV-III Christmas disease patients, treated only with NHS IX and with no other risk factors, argues strongly for haste with manufacture of heated factor IX."
BPL had started to heat treat its Factor 8 and "limited amounts will be distributed to the National Health Service for clinical trials within the next two weeks. Heat-treatment capacity is being increased, and it is hoped that, by April this year, all BPL factor VIII will be heat-treated." Read more about BPL had started to heat treat its Factor 8 and "limited amounts will be distributed to the National Health Service for clinical trials within the next two weeks. Heat-treatment capacity is being increased, and it is hoped that, by April this year, all BPL factor VIII will be heat-treated."